New drug trial targets debilitating fatigue from Tick-Borne parasite
NCT ID NCT06656351
First seen Nov 01, 2025 · Last updated Apr 12, 2026 · Updated 19 times
Summary
This study is testing whether the drug tafenoquine can help people with chronic babesiosis who suffer from severe, disabling fatigue. The main goal is to see if the treatment reduces fatigue levels and clears the Babesia parasite from the body. Researchers will enroll 40 adults and follow them for 180 days to measure their fatigue and check for the parasite using blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC BABESIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.